From LDL infiltration to foam cells, fibrous caps and rupture risk — and how statins interrupt the process both by lowering LDL and by stabilizing existing plaque
Atherosclerosis begins silently, often decades before any symptom appears. Circulating low-density lipoprotein (LDL) particles — cholesterol-carrying spheres coated by apolipoprotein B-100 — cross the endothelial monolayer at sites of turbulent flow or endothelial dysfunction and become trapped within the subendothelial space by binding to wall proteoglycans. Once retained, LDL is exposed to reactive oxygen species and enzymes that oxidize it into a biologically aggressive form: oxidized LDL (ox-LDL). This single modification transforms an inert lipid particle into a potent inflammatory trigger.
LDL transit into the arterial wall is not passive leakage but a regulated, flow-dependent process:
• Transcytosis: LDL crosses endothelial cells via receptor-mediated transcytosis (SR-BI-dependent), concentrated at branch points and bifurcations where shear stress is low or disturbed • Endothelial dysfunction: hypertension, smoking, hyperglycemia, and elevated LDL itself increase endothelial permeability and adhesion molecule expression (VCAM-1, ICAM-1) • Proteoglycan trapping: apoB-100 binds arterial wall proteoglycans (biglycan, versican) via basic amino acid residues — the "response-to-retention" hypothesis — anchoring LDL in the intima rather than allowing efflux back to plasma • Residence time: trapped LDL persists in the wall for extended periods, providing a window for enzymatic and oxidative attack that would not occur in fast-flowing plasma
Retained LDL is progressively modified by the local wall environment:
• Minimally modified LDL (mmLDL): early oxidation of phospholipids only, still recognized by native LDL receptor • Oxidized LDL (ox-LDL): further oxidation of both lipid and apoB-100 protein by reactive oxygen species, myeloperoxidase, and lipoxygenases — no longer recognized by the native LDL receptor • Neoepitope formation: oxidized apoB-100 exposes novel epitopes recognized by scavenger receptors (SR-A, CD36) on macrophages and by natural IgM autoantibodies • Consequence: ox-LDL is directly cytotoxic to endothelium, chemotactic for monocytes, and — critically — undergoes unregulated ("scavenger") uptake that does not shut off as intracellular cholesterol rises
Unlike the native LDL receptor, scavenger receptors are not down-regulated by rising intracellular cholesterol. This lack of feedback inhibition is precisely why macrophages that ingest ox-LDL become progressively engorged with lipid — setting up the foam cell transformation of the next stage.
Oxidized LDL in the intima triggers a local inflammatory response. Endothelial cells display adhesion molecules that capture circulating monocytes, which roll, adhere, and migrate into the wall under chemotactic signals such as MCP-1. Once resident, monocytes differentiate into macrophages and begin consuming ox-LDL through scavenger receptors. Because this uptake pathway is not feedback-regulated, the macrophages become progressively engorged with cholesteryl ester droplets, taking on a foamy, vacuolated appearance under the microscope — the foam cell. Aggregates of foam cells beneath the endothelium constitute the fatty streak, the first grossly visible atherosclerotic lesion.
The transition from a lipid problem to an inflammatory disease happens here:
• Adhesion cascade: selectins slow monocytes (rolling) → integrins (VLA-4/VCAM-1) create firm adhesion → transmigration through the endothelial junction into the intima • Differentiation: once in the wall, monocytes differentiate into macrophages under the influence of M-CSF, upregulating scavenger receptor expression • Amplification loop: activated macrophages secrete additional cytokines (TNF-α, IL-1, IL-6) that further activate endothelium and recruit more monocytes — a self-reinforcing inflammatory cycle
• Cholesteryl ester accumulation: macrophages esterify free cholesterol from ingested ox-LDL via ACAT1, storing it in cytoplasmic droplets that give the classic "foamy" histologic appearance • Efferocytosis failure: in early lesions, dying foam cells are normally cleared by neighboring phagocytes (efferocytosis); as the lesion matures this clearance becomes defective, and uncleared debris contributes to a growing necrotic/lipid core rather than being resolved • Fatty streak: macroscopically visible as a thin, flat, yellow discoloration on the intimal surface — present in the aorta of most people by their teens, and in the coronary arteries by their 20s
The fatty streak is clinically silent and, importantly, still reversible if the driving stimulus (elevated LDL, inflammation) is reduced. It is the subsequent recruitment of smooth muscle cells and fibrous cap formation — not the fatty streak itself — that commits the lesion toward a more permanent, potentially unstable plaque.
As the lesion matures, platelet-derived growth factor (PDGF) and other mitogens released by activated macrophages and endothelium recruit smooth muscle cells from the underlying media. These cells migrate into the intima, switch from a contractile to a synthetic phenotype, proliferate, and lay down a collagen- and proteoglycan-rich extracellular matrix. This matrix forms the fibrous cap — a mechanical barrier that separates the thrombogenic lipid/necrotic core from the flowing blood. The thickness and integrity of this cap, more than the overall size of the plaque, is what determines whether a lesion remains clinically silent or ruptures to cause a heart attack or stroke.
• Signal source: macrophages and injured endothelium release PDGF-BB, a potent SMC chemoattractant and mitogen • Phenotypic switch: medial SMCs shift from a quiescent "contractile" phenotype to a proliferative "synthetic" phenotype, down-regulating contractile proteins (α-actin, myosin) and up-regulating matrix-producing machinery • Migration: SMCs cross the internal elastic lamina into the intima and position themselves over the developing lipid core, between the core and the lumen
The cap is a dynamic structure whose stability reflects a balance, not a fixed state:
• Synthesis side: synthetic-phenotype SMCs produce type I/III collagen, elastin, and proteoglycans that give the cap tensile strength • Degradation side: activated macrophages within and beneath the cap secrete matrix metalloproteinases (MMP-2, MMP-9, MMP-1) that break down collagen; ongoing inflammation tips this balance toward degradation • Thin-cap fibroatheroma: when a lipid-rich necrotic core is covered by a cap thinner than roughly 65 µm and infiltrated by macrophages, the lesion is classified as a "vulnerable plaque" with high rupture risk • Clinical consequence: rupture exposes highly thrombogenic core material to flowing blood, triggering platelet activation and coronary/cerebral thrombosis — the proximate cause of most heart attacks and many strokes
Counterintuitively, plaques that cause acute events are often only moderately obstructive on angiography — it is cap fragility, not luminal narrowing, that predicts rupture. This is exactly the property statins act on beyond their LDL-lowering effect, discussed in Stage 5.
Statins are the cornerstone pharmacologic intervention for atherosclerosis prevention. They competitively and reversibly inhibit HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway that hepatocytes use to synthesize cholesterol. With intracellular cholesterol synthesis reduced, hepatocytes sense the shortfall and respond by upregulating LDL receptor (LDLR) expression on their surface via the SREBP-2 transcription factor pathway. These additional receptors pull more circulating LDL out of the bloodstream and into the liver for clearance — lowering plasma LDL by roughly 30–55% depending on the agent and dose, and directly reducing the amount of LDL available to infiltrate the arterial wall.
• Mevalonate pathway: HMG-CoA reductase converts HMG-CoA to mevalonate, the committed step toward cholesterol (and isoprenoid) synthesis • Competitive inhibition: statins structurally resemble HMG-CoA and occupy the enzyme active site, reducing hepatic cholesterol output • Sensing the shortfall: falling intracellular (hepatocyte) cholesterol releases SREBP-2 from ER membrane retention, allowing it to travel to the nucleus and activate transcription of cholesterol-pathway genes — including the LDL receptor gene
• More receptors, more clearance: increased hepatocyte-surface LDLR density increases the rate of receptor-mediated endocytosis of circulating LDL particles • Dose-response: reduction in plasma LDL scales with statin potency and dose — low-to-moderate intensity regimens reduce LDL roughly 20–35%, high-intensity regimens (high-dose atorvastatin or rosuvastatin) achieve 40–55%+ • Downstream effect: with less circulating LDL, less substrate is available to infiltrate the arterial wall and drive the oxidation → foam cell → lipid core sequence described in Stages 1–3, slowing new lesion formation and progression
The Cholesterol Treatment Trialists' (CTT) meta-analysis found that each 38.7 mg/dL (1 mmol/L) reduction in LDL cholesterol is associated with roughly a 22% relative reduction in major vascular events — a remarkably consistent, near-linear dose-response relationship seen across dozens of statin trials.
LDL lowering alone does not fully explain the clinical benefit of statins, particularly the relatively rapid reduction in cardiovascular events seen within months of starting therapy — faster than plaque regression by lipid lowering alone could plausibly explain. Statins also exert "pleiotropic" effects independent of cholesterol synthesis inhibition: they reduce vascular and systemic inflammation, suppress macrophage activation and MMP secretion within existing plaques, and thereby help reinforce the fibrous cap of lesions that are already present. The net effect is a plaque that is less likely to rupture, even before its lipid content has meaningfully shrunk.
• Reduced isoprenoid signaling: inhibiting the mevalonate pathway also reduces synthesis of isoprenoid intermediates needed for the activation of small GTPases (Rho, Rac) that drive macrophage migration and inflammatory signaling • Lower systemic inflammation: statins reduce circulating high-sensitivity C-reactive protein (hs-CRP), a marker of vascular inflammation, largely independent of the degree of LDL lowering achieved • Reduced macrophage burden: fewer activated macrophages infiltrate and persist within existing plaque, reducing local cytokine and MMP output at the cap
• Rebalancing cap turnover: with MMP-2/9 secretion suppressed and collagen breakdown slowed, the synthesis-versus-degradation balance in the cap (see Stage 3) shifts back toward net reinforcement, thickening and stabilizing the cap over existing lesions • Endothelial function: statins improve endothelial nitric oxide bioavailability, supporting vasodilation and reducing further monocyte adhesion • Composite effect: the combination of a smaller LDL-driven lipid supply (Stage 4) and a mechanically stronger cap over existing plaque (this stage) together lower the probability of plaque rupture and acute thrombosis, translating into fewer heart attacks and strokes for a given amount of plaque present
The JUPITER trial enrolled patients with LDL already in a normal range but elevated hs-CRP, and still found a significant reduction in cardiovascular events with rosuvastatin. This is strong evidence that statins reduce risk through mechanisms beyond LDL lowering alone — direct support for the plaque-stabilization pathway described here.